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Abstract
Background: The massive scale-up of antiretroviral treatment (ART) access worldwide has brought tremendous
benefit to populations affected by HIV/AIDS. Optimising HIV care in countries with diverse medical systems is
critical; however data on best practices for HIV healthcare delivery in resource-constrained settings are limited. This
study aimed to understand patient characteristics and treatment outcomes from different HIV healthcare settings in
Bangalore, India.
Methods: Participants from public, private and public-private HIV healthcare settings were recruited between 2007
and 2009 and were administered structured interviews by trained staff. Self-reported adherence was measured
using the visual analogue scale to capture adherence over the past month, and a history of treatment interruptions
(defined as having missed medications for more than 48 hours in the past three months). In addition, CD4 count
and viral load (VL) were measured; genotyping for drug resistance-associated mutations was performed on those
who were in virological failure (VL > 1000 copies/ml).
Results: A total of 471 individuals were included in the analysis (263 from the public facility, 149 from the public-
private facility and 59 from the private center). Private facility patients were more likely to be male, with higher
education levels and incomes. More participants reported ≥ 95% adherence among public and public-private
groups compared to private participants (public 97%; private 88%; public-private 93%, p < 0.05). Treatment
interruptions were lowest among public participants (1%, 10%, 5% respectively, p < 0.001). Although longer clinic
waiting times were experienced by more public participants (48%, compared to private 27%, public-private 19%, p
< 0.001), adherence barriers were highest among private (31%) compared with public (10%) and public-private
(17%, p < 0.001) participants. Viral load was detectable in 13% public, 22% private and 9% public-private
participants (p < 0.05) suggesting fewer treatment failures among public and public-private settings. Drug
resistance mutations were found more frequently among private facility patients (20%) compared to those from
the public (9%) or public-private facility (8%, p < 0.05).
Conclusions: Adherence and treatment success was significantly higher among patients from public and public-
private settings compared with patients from private facilities. These results suggest a possible benefit of the
standardized care delivery system established in public and public-private health facilities where counselling by a
multi-disciplinary team of workers is integral to provision of ART. Strengthening and increasing public-private
partnerships can enhance the success of national ART programs.
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Although the HIV epidemic may show signs of levelling
off in some parts of the world [1], the overwhelmingly
high numbers of people living with HIV in Asia and
Sub-Saharan Africa continue to fuel efforts in capacity-
building, improving existing infrastructure and widening
antiretroviral therapy (ART) access in areas that are
most affected. The United Nations Secretary-General,
Mr. Kofi Annan, stated in 2001 that,“People no longer
accept that the sick and dying, simply because they are
poor, should be denied drugs which have transformed
the lives of others who are better off” [2]. It was with
Kofi Annan’s lofty goal in mind that in 2004, the politi-
cal leaders in India and the National AIDS Control
Organization (NACO) initiated the National AIDS Con-
trol Program that provided free antiretroviral treatment
access to all those in the nation who had a medical
need for these drugs. Starting with just eight centers in
2004, this Program grew exponentially, and currently
there are almost 300 ART Centers across the country
serving over 360,000 adults and 22,000 children with
antiretroviral medications [3]. Today, much of the HIV
care, treatment and support in India is provided through
NACO-run ART centres [3]. Following a diagnosis of
HIV infection and assessment of the need for medica-
tion, patients within these ART Centres are provided
first-line ART free of cost along with intensive counsel-
ling at each visit. Services in these centers are fully
financed and delivered by the public sector in accor-
dance with strict treatment guidelines set by the
National Program [4].
Although the bulk of the HIV healthcare system is
handled by the national government, it is important to
note that the health sector in India is highly pluralistic;
multiple systems of medicine including alternative and
indigenous medicine are legally practiced in diverse
institutional settings [5].T h ec o u n t r ya l s oh a so n et h e
most highly privatized health care systems in the world;
out-of-pocket payments account for 72% of total health-
care spending in India [6]. HIV care is also delivered in
the private sector where approximately 35,000-50,000
patients are managed by a private physician of their
choice, and payment for consultation and treatment are
largely made out-of-pocket [7,8]. While there also exists
a small philanthropic private sector that includes non-
governmental organizations that medically and finan-
cially support disadvantaged patients, this paper refers
to the formal private health care sector where patients
pay for their treatment. With the aim of increasing
access to ART, the National AIDS Control Program in
India has partnered with reputed private institutions to
deliver ART through an innovative partnership
approach. The public-private partnership here is a colla-
boration between the government National AIDS
control program and the private entity, wherein the for-
mer provides first-line ART free of cost to all patients
registered at the center, while the private hospital pro-
vides the premises, infrastructure and human resources.
There are fifteen such public-private partnership ART
Centers in the country at present, which altogether pro-
vide care to over 21,000 patients [3]. The public-private
centers also operate under the standardized national
program treatment guidelines.
As there is wide variation in patient demographics,
motives for attendance at a particular sector, system of
medical care and drug dispensation methods among
these three healthcare systems, it is likely that adherence
levels and treatment outcomes also vary among the
three settings. In particular, we hypothesized that the
standardized system consisting of a high emphasis on
counselling and multidisciplinary approach present
within the public HIV healthcare system, will have a
positive impact on adherence levels among patients and
hence treatment outcome. The objective of this descrip-
tive paper was to compare the differences in patient
characteristics, adherence, indicators of care, virological
failure and drug resistance among fully public, public-
private and fully private HIV care-giving centers in Ban-
galore, India.
Methods
Study setting
This study was done at three types of clinics in South
India: public, public-private, and fully private. (i) The
public facility was represented by government ART Cen-
ters located at large state-run public hospitals, predomi-
nantly the Bowring and Lady Curzon Hospital. The
public centers operate under the NACO program guide-
lines. Briefly, the NACO program insists on multi-disci-
plinary care with comprehensive services provided by a
physician, nurse, counsellor, and pharmacist within the
same setting for each patient, with great emphasis
placed on intense counselling sessions prior to initiation
of ART and at each subsequent visit. (ii) The public-pri-
vate facility was the ART Center at St. John’s Hospital, a
missionary teaching hospital. The public-private partner-
ship here is a collaboration between NACO and the
teaching hospital, wherein the former provides NACO-
recommended fixed dose combination first-line ART to
all patients registered at the center, while the private
teaching hospital provides the premises, infrastructure
and human resources. The public-private center also
operates under the NACO program guidelines. All
patients attending the first two types of clinics, the pub-
lic and the public-private facility, are treated free of cost
at the point of service. (iii) The private facility was the
o u t - p a t i e n td e p a r t m e n ta tS t .J o h n ’sH o s p i t a l ,w h e r e
patients are treated independently by their respective
Shet et al. BMC Health Services Research 2011, 11:277
http://www.biomedcentral.com/1472-6963/11/277
Page 2 of 8physicians and out-of-pocket payments for health ser-
vices and medications are made by the patients
themselves.
Study populations and design
Study participants included HIV-infected adults taking reg-
ular ART who were part of a two-year observational cohort
to study adherence at the three centers [9]. Potential partici-
pants were first referred by their physicians or counsellors,
and those who agreed were escorted to a separate room for
informed consent and an approximately 1-hour study inter-
view. The recruitment procedure remained uniform across
all the health care settings. Patients in the public and private
clinics were recruited over a two year period beginning in
August 2007. Patients in the public-private clinic were
recruited from March 2008 after the inception of the ART
Center. Attendance of the patients was exclusive to a parti-
cular clinic, and only those patients who had been with
each clinic for a minimum consecutive period of six months
were included in this analysis. Cross-sectional data from
these patients at six months after recruitment into the
study were used in this analysis.
Data collection
Participants were referred to the study by their physicians,
by the outpatient clinic clerk, or by screening staff at out-
patient clinic registration. Following administration of
informed consent, a face-to-face interview was adminis-
tered by trained study staff members whoS were not part
of the regular clinical care-giving team. The interview
questionnaire was developed in English, translated into
Kannada, Tamil and Telugu, and independently back-
translated into English to ensure semantic equivalence
[10]. The interview lasted approximately one hour and
assessed a variety of topics, including demographics and
health history, medical regimen, adherence barriers and
other psychosocial factors. Health history included time of
first diagnosis and initiation of ART as well as number
and reason for health care visits in the past 3 months.
Information was recorded on perceived adherence and
psychosocial barriers such as (i) lack of routine barriers
(forgetting, being away from home, being busy with other
events) (ii) refill related barriers (didn’tw a n tt op u r c h a s e
in same community, ran out before refill possible, no
money, no stock) (iii) regimen-related barriers (side effects,
feeling that medicines were harmful) and (iv) health-
related barriers (feeling sick or depressed, feeling healthy
enough to skip, alcohol abuse). Disclosure and perceived
adherence support were assessed for different categories of
people such as spouse, parents, children, siblings, other
relatives, friends or co-workers. Patients also were asked
about their ease of communication with their doctor, and
potential barriers to keeping appointments such as long
clinic waiting times or lack of child care.
Adherence measurement: Self reported adherence for
the last one month was measured using the visual analo-
gue scale (VAS), which has been validated as a simple
and useful measure of self-reported adherence [11,12].
The VAS is a horizontal line ranging from 0 to 100, on
which respondents point to a spot on the line that cor-
responds to the percentage of prescribed pills taken.
Treatment interruptions were defined as having missed
medications for more than 48 hours in the past three
months.
Laboratory tests: Blood samples were drawn every six
months for measuring CD4 counts (single platform flow
cytometry assay; Guava Technologies Inc., Hayward,
CA, USA) and plasma viral load (in-house Real Time
PCR assay; Molecular Diagnostics and Genetics, Reli-
ance Life Sciences, Mumbai, India). Plasma viral load of
< 100 copies/ml was defined as undetectable viral load,
consistent with treatment success. Those patients whose
viral load at either recruitment or month 6 exceeded
1000 copies/ml were sampled for drug resistance geno-
typing assays (YRGcare, Chennai, India, using an in-
house real time PCR method [13]) to assess the accu-
mulation of mutations over time.
Statistical analysis
Univariate descriptive statistics were calculated for con-
tinuous variables; frequencies and percentages were
used for categorical variables, both for the overall sam-
ple and according to type of center. Significance of asso-
ciation with type of center was assessed via Kruskal-
Wallis tests for continuous variables. For categorical
variables, chi-square tests were used to assess overall
significance, and its adjusted standardized residuals to
assess deviation from chance for each type of center. In
addition, logistic regression with robust standard errors
was performed for the outcomes related to virological
failure and drug resistance. We considered gender, mari-
tal status, education, residence), disclosure, adherence
barriers, regimen switch, side effects, income and dura-
tion of ART (in months) as potential confounders, but,
due to limited statistical power, only included those
variables that were significantly bivariately related to the
outcome, in the multivariate models. Regression analyses
were performed in Stata, version 11, while all other ana-
lyses were performed in SPSS, version 18.
The study protocol was approved by the Institutional
Review Boards at the University of California, San Fran-
cisco and the St John’s National Academy of Health
Sciences, Bangalore.
Results
Socio-demographic characteristics
A total of 471 patients met inclusion criteria for this
analysis and were studied in the three types of facilities;
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private facility, and 149 from the public-private facility
(Table 1). Two-thirds of the patients were male, with a
significantly higher proportion of males attending a pri-
vate facility (p = 0.001). Private facility patients were
also more likely to have a higher level of education (p <
0.01) and have higher incomes (p < 0.01). While the
public facility had three-quarters of patients residing
within the city and another 23% visiting from other
parts of the state, the private and public-private facilities
received a larger proportion of patients (19% and 18%,
respectively, p < 0.001) from neighbouring states. HIV
clinical stage before initiation of ART and mean baseline
CD4 did not differ significantly among the three groups.
The median duration of ART for all patients was 22
months (range: 6-54 months; 27 months, 28 months
and 11 months for public, private and public-private set-
tings respectively, p < 0.001). Ninety-eight percent of
patients in all the centers were on treatment with the
standard ART regimen recommended by the national
guidelines [4]; 2 nucleoside reverse transcriptase inhibi-
tors (NRTI) plus 1 non-nucleoside reverse transcriptase
inhibitors (NNRTI) (100% public, 92% private, and 98%
public-private facility patients; p < 0.001). The regimens
most commonly included zidovudine or stavudine plus
lamivudine as the NRTI backbone and nevirapine or
efavirenz as the NNRTI component. Nine of the 10 pri-
vate sector patients who were not on these regimens
were on a tenofovir-containing regime.
Disclosure of infection status and adherence support
Patients attending a private facility had disclosed their HIV
status to a mean of 3.9 categories of persons, compared to
3.5 in the public setting, and 2.5 reported by patients
attending a public-private facility (p < 0.001). The spouse
was the most common member who was privy to the
participants’ HIV status. Among married private center
participants, 84% had disclosed to their spouse, compared
to 66% public and 51% public-private participants (p <
0.001). However the perceived support for adherence that
participants received from family members and friends
appeared similar across all three categories of participants,
as around 80% in each group reported that they received
help in taking their medications. Non-relatives had a big-
ger role in providing adherence support to public facility
participants (6%), compared to private (2%) and public-
private participants (1%, p < 0.05).
Health system access
All patients attending public or public-private facilities
reported at least one visit to a health care provider
within the preceding 3 months. The seven patients who
reported no contact with their health care provider
within the same period were all attending a private facil-
ity. While 91% of patients from the public and the pub-
lic-private facilities reported a prescription refill as at
least part of the reason for their visit, only 58% of pri-
vate sector patients contacted their healthcare provider
for the same reason (p < 0.001). When queried about
their perceived ease of communicating with their treat-
ing physician, three-quarters of patients (75%) in the
public-private facility said they asked their physician
questions at every visit, in contrast to 68% and 59% in
the private and public facility respectively (p < 0.01).
More public clinic patients (48%) perceived difficulty
with long clinic waiting times compared to private
(27%) and public-private setting patients (19%, p <
0.001).
Adherence and barriers of adherence
The percent of participants with ≥95% adherence in the
past month was 97% in the public setting, 88% in the
Table 1 Socio-demographic characteristics of patients from different clinic settings, n (%)
All (n = 471) n (%) Type of HIV healthcare setting
Public (n = 263) Private (n = 59) Public-private (n = 149) p-value
Gender: Male 317 (67) 185 (70) 47 (80) 83 (56) < 0.001
Age in years: mean (SD) 37.3 (8.6) 36.9 (8.5) 40.4 (9.6) 36.9 (8.4) 0.013
Residence: < 0.001
Bangalore/Karnataka 427 (91) 257 (98) 48 (81) 122 (82)
Neighbour states 44 (9) 6 (2) 11 (19) 27 (18)
Marital status: 0.700
Married 332 (70) 182 (69) 44 (75) 106 (71)
Never married/widowed/separated/divorced 139 (30) 81 (30) 15 (25) 43 (29)
Education: 0.001
≥ 10 yrs schooling 127 (27) 68 (26) 23 (39) 36 (24)
Employed 345 (73) 208 (79) 44 (75) 93 (62) < 0.001
Annual income (USD), median (range) 803 (0-16,056) 803 (0-6,684) 1068 (0-16,056) 535 (0-5,083) 0.001
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0.05) (Table 2). Treatment interruptions lasting longer
than 48 hours within the past 3 months were reported
with greater frequency among those in the private facil-
ity (10%) compared to those in the public facility (1%),
or the public-private facility (5%) (p = 0.001). A total of
14% (n = 68) of patients across the three facilities
reported experiencing at least one adherence barrier.
The most common barriers expressed were related to
lack of routine (such as being away from home, being
busy with other things, and simply forgetting). A quarter
of all private clinic patients experienced these “lack of
routine” barriers compared with only 11% in the public-
private and 8% in the public facilities respectively (p =
0.001). Refill-related barriers were expressed by only 1%
of patients, almost exclusively by private facility patients,
the major constraint being the ability to pay for the
drugs. Drug supply appeared to be consistent and none
of the participants reported non-availability of medicines
as a barrier.
Treatment failure and drug resistance
A detectable viral load was found in 13% of public facil-
ity, 22% of private facility, and 9% of public-private
patients (p < 0.05) (Table 2). The presence of drug resis-
tance-associated mutations was assessed for those
patients who had viral load > 1000 copies/ml (n = 63).
More patients from the private center compared to the
other centers had their samples sent for genotyping
( p u b l i c1 1 % ;p r i v a t e ,2 5 % ;a n dp u b l i c - p r i v a t e ,1 2 % ;p<
0.05) and drug resistance mutations were present
among 20% of the private sector patients compared to
less than 10% of patients in the public and public-pri-
vate setting (p < 0.05) (Table 2). Logistic regression
showed that patients from the private facility were 2.7
times more likely to have drug resistance mutations
compared to those from the public facility (Unadjusted
OR 2.66, 95% CI 1.24-5.73) (Table 3). The increased
odds for development for drug resistance among the
private facility patients remained significant even after
adjusting for duration of antiretroviral therapy, marital
status and adherence barriers, which were significant
predictors in the bivariate analyses.
Discussion
This detailed comparison of the characteristics and
behaviours of patients in different healthcare systems in
HIV care in India gives us new insights into healthcare
outcomes in relation to healthcare settings. We have
found that despite having lower income and higher
healthcare barriers such as prolonged clinic waiting
times, patients in the public health care facility had sig-
nificantly better adherence levels, higher viral suppres-
sion rates and lower drug resistance prevalence
compared to patients accessing care in the private facil-
ity, suggesting superior treatment outcomes among
patients in the public healthcare setting.
Previous analysis of the entire cohort of 552 partici-
pants at baseline demonstrated a strong association
between suboptimal adherence, treatment failure and
drug resistance [9]. Adherence to ART is influenced by
numerous factors, including state of health, travel or
migration, adverse effects, stigmatization and financial
constraints. Cost of ART has been identified as a barrier
of adherence in several studies; in a study from Bots-
wana, adherence was predicted to increase by 20% if
cost were removed as a barrier [14]. Among 150 sub-
jects recruited in Tanzania poor adherence and virologi-
cal failure appeared to be strongly correlated to self-
funded ART [15]. Cost of ART was found to be a signif-
icant correlate of self-reported adherence among
patients attending private clinics in Mumbai [16], and
was an important barrier of adherence discussed among
a large majority of patients interviewed in Chennai [17].
Table 2 Adherence and treatment failure among the three types of healthcare settings: n (%)
Type of healthcare setting
Public (n = 263) Private (n = 59) Public-private (n = 149) P value
≥95% adherence
a reported in previous one month 256 (97.3) 52 (88.1) 139 (93.3) 0.01
Treatment interruption reported in previous 3 months 2 (0.8) 6 (10.2) 8 (5.4) 0.001
Detectable
b viral load 35 (13.3) 13 (22.0) 14 (9.4) 0.05
CD4 ≥ 200 cells/mm
3 207 (78.7) 47 (79.7) 119 (79.9) n.s.
d
Genotyping
c performed 29 (11.0) 15 (25.4) 19 (12.8) 0.019
Drug resistance-associated mutations present 23 (8.7) 12 (20.3) 12 (8.1) 0.029
a Adherence as measured by Visual Analogue Scale (VAS)
b Detectable viral load: > 100 copies/ml
c Genotyping was performed on those with viral load > 1000 copies/ml
d Not significant
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LINC), a strong relationship was found between receipt
of ART and survival, with the greatest survival benefit
being when ART was administered free of cost to
patients in resource-limited areas [18]. It is conceivable
that the removal of cost as an adherence barrier among
patients in the public and public-private healthcare sys-
tems has a strong role in the adherence and treatment
outcomes seen in our study.
The value of an educational and counselling interven-
tion in improving adherence has been well recognized
[19]. A Cochrane review concluded that patient support
and educational interventions particularly those target-
ing coping skills, that are administered over the ART
initiation period were indeed associated with improved
adherence outcomes [20]. Thus the system practised in
the public and public-private settings where counselling
is an integral part of HIV care is likely to have influ-
enced the higher adherence rates noted in these settings.
Although medical providers in private settings do offer
adherence support, the lack of a standard counselling
protocol often results in a wide range in the quality and
impact of counselling support in private clinics.
The past decade has witnessed a massive scale-up of
antiretroviral programs in Asia, particularly India.
Today, there are 2.3 million persons in India living with
HIV, equivalent to approximately 0.3 percent of the
adult population, which is a 67% reduction from early
prevalence reports in 2005-2006 [3]. India is a large,
diverse country with complex social issues which is a
challenge to any national medical program. However the
country has a well- articulated national strategy which is
described in the National AIDS Control Program III
(NACP III) [21] and is anchored in the principles of
health promotion efforts while seeking to integrate pre-
vention with care, support and treatment. The Program
hence utilizes public, nongovernmental and private
health institutions to carry out its functions of preven-
tion, care and treatment. The supply chain management
of anti-retroviral drugs is managed through a separate
team that is responsible for maintaining a continuous
supply of ARV drugs. Clearly articulated operational
guidelines for ART centers lay the framework for the
standard of care that is provided at these centers [22].
Counseling for the patient is emphasized at every stage;
from the initial health seeking visit, to diagnosis and
evaluation of clinical stage, to initiation and mainte-
nance on ART. ART centers are also linked to commu-
nity care centres which are set up within the non-
governmental organization (NGO) sector with the main
objective of providing psycho-social support, ensuring
drug adherence and providing home-based care [23].
National data indicate that among all patients who have
been initiated on ART so far, 11% have died, 0.65% have
discontinued treatment, and only 9% patients are miss-
ing or lost-to-followup [23]. Similar results were seen in
a systematic study conducted at 3 government ART
centers in India [24].
In order to widen their reach towards people from dif-
ferent socio-economic backgrounds, NACO has estab-
lished several public-private partnerships in NGOs and
private medical colleges structured such that both the
government and the private institution have an equal
role in maintaining the quality of care offered at these
centres. It is increasingly believed that under such part-
nerships, public and private sectors can play innovative
roles in financing and providing health care services,
particularly in India [25-27]. In the public-private ART
center model, the entire systems of counselling, encour-
agement of treatment supporters during the initial visits
during the start of ART, multidisciplinary teamwork and
patient flow, are maintained in a similar manner com-
parable to the system established within the public cen-
ters. Our data clearly show that health outcome as
measured by adherence levels and virological suppres-
sion was clearly optimal in the public-private facility
compared to the fully private setting.
Cost of antiretroviral drugs has been implicated as a
major factor influencing adherence, although the litera-
t u r ei sd i v i d e do nt h i si s s u e[ 2 8 ] .A nI n d i a ns t u d yo f
HIV-infected patients from Pune and Delhi has shown
that adherence was higher among patients paying out-
of-pocket compared to those who were receiving free
ART via an employee-insurance program; the investiga-
tors concluded that provision of free ART without ade-
quate counselling and adherence support was likely to
weaken treatment success [29]. Our study also under-
scores the critical role played by the standardized
Table 3 Risk for drug resistance among different clinic settings
Type of healthcare setting Unadjusted risk for drug
resistance
Adjusted risk adjusted for marital status, barriers of adherence, time on
ART
a
OR 95% CI p-value OR 95% CI p-value
Private 2.66 1.24-5.73 0.012 2.53 1.13-5.66 0.02
Public-private 0.91 0.44-1.90 0.809 1.17 0.51-2.69 0.72
Public 1 (reference category) 1 (reference category)
a Factors that were not significantly associated were gender, residence, education, income, disclosure status, side effects, and regimen switch.
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support that is in-built into the ART clinics across the
country.
There are several limitations with this study. The
numbers studied were relatively small, and the patient
numbers were dissimilar in the different settings. The
public-private facility was newly begun and was reflected
in the short duration of ART that the participants from
this setting experienced. The relative youth of the center
may have unduly influenced the lower proportion of
those with detectable viral load although factors such as
systematic counselling and better adherence may have
also influenced the outcome. In addition, the private
and public-private settings were located within the same
institution, although it is important to note here that
there was no overlap of patients or medical care provi-
ders, and the two settings were geographically separate
in different locations. In contrast, the presence of both
settings within the same institution may be seen as an
advantage; the single geographical location may have
minimized the heterogeneity of patients and lent more
significance to the positive outcome noted in the public-
private facility. It is also possible that these results may
be indicative of the individual center and not the public-
private or private category on the whole as only one
such center each was included in the study. However
the relative homogeneity of the organizational capacity
of the public centers is assured by the National AIDS
Control Program guidelines [21,22], and it is likely that
the public-private and private centers included in the
study are also representative of other similar settings in
the country. Additional research would be necessary to
see if these findings can be replicated in other settings.
It is noteworthy that since this is a cross-sectional
study, no conclusions can be drawn regarding cause and
effect. These limitations notwithstanding, the results of
this study are strongly suggestive of the larger benefit of
including strict standardized counselling guidelines and
establishing a multi-faceted paradigm of medical care
that is prevalent in the public and public-private HIV
care facilities established under the National AIDS Con-
trol Program in India.
Conclusions
The results of this comparison study indicate that, com-
pared to fully private HIV healthcare systems where
patients report better employment rates and higher
socioeconomic standards, adherence and virological sup-
pression is better maintained within the public and pub-
lic-private health care setting where counselling is
integral to provision of care and ART, and where a
multi-disciplinary team of workers are involved in HIV
healthcare delivery. While better outcomes are clearly
seen in the public and public-private health care settings
included in this study, larger multicentric studies are
required to support this preliminary information. Over-
all the results clearly imply that strengthening patient
support mechanisms and increasing public-private parti-
cipation may be an effective global approach towards
diminishing the burden of HIV infection worldwide.
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